source,target,type,evidence,source_type,score,id
pembrolizumab,MET,drug_gene_cooccurrence,Co-occurrence in text: Pembrolizumab Plus Chemotherapy Per PD-L1 Stratum In Patients With Metastatic Non-Small Cell Lung Cancer: Real-World Effectiveness Versus Trial Efficacy.. Clinical trial efficacy and real-world effect...,cooccurrence,0.6,e0
AR,lung cancer,biomarker_cancer_cooccurrence,Co-occurrence in text: Pembrolizumab Plus Chemotherapy Per PD-L1 Stratum In Patients With Metastatic Non-Small Cell Lung Cancer: Real-World Effectiveness Versus Trial Efficacy.. Clinical trial efficacy and real-world effect...,cooccurrence,0.7,e1
AR,non-small cell lung cancer,biomarker_cancer_cooccurrence,Co-occurrence in text: Pembrolizumab Plus Chemotherapy Per PD-L1 Stratum In Patients With Metastatic Non-Small Cell Lung Cancer: Real-World Effectiveness Versus Trial Efficacy.. Clinical trial efficacy and real-world effect...,cooccurrence,0.7,e2
ER,lung cancer,biomarker_cancer_cooccurrence,Co-occurrence in text: Pembrolizumab Plus Chemotherapy Per PD-L1 Stratum In Patients With Metastatic Non-Small Cell Lung Cancer: Real-World Effectiveness Versus Trial Efficacy.. Clinical trial efficacy and real-world effect...,cooccurrence,0.7,e3
ER,non-small cell lung cancer,biomarker_cancer_cooccurrence,Co-occurrence in text: Pembrolizumab Plus Chemotherapy Per PD-L1 Stratum In Patients With Metastatic Non-Small Cell Lung Cancer: Real-World Effectiveness Versus Trial Efficacy.. Clinical trial efficacy and real-world effect...,cooccurrence,0.7,e4
MET,lung cancer,biomarker_cancer_cooccurrence,Co-occurrence in text: Pembrolizumab Plus Chemotherapy Per PD-L1 Stratum In Patients With Metastatic Non-Small Cell Lung Cancer: Real-World Effectiveness Versus Trial Efficacy.. Clinical trial efficacy and real-world effect...,cooccurrence,0.7,e5
MET,non-small cell lung cancer,biomarker_cancer_cooccurrence,Co-occurrence in text: Pembrolizumab Plus Chemotherapy Per PD-L1 Stratum In Patients With Metastatic Non-Small Cell Lung Cancer: Real-World Effectiveness Versus Trial Efficacy.. Clinical trial efficacy and real-world effect...,cooccurrence,0.7,e6
PD-L1,lung cancer,biomarker_cancer_cooccurrence,Co-occurrence in text: Pembrolizumab Plus Chemotherapy Per PD-L1 Stratum In Patients With Metastatic Non-Small Cell Lung Cancer: Real-World Effectiveness Versus Trial Efficacy.. Clinical trial efficacy and real-world effect...,cooccurrence,0.7,e7
PD-L1,non-small cell lung cancer,biomarker_cancer_cooccurrence,Co-occurrence in text: Pembrolizumab Plus Chemotherapy Per PD-L1 Stratum In Patients With Metastatic Non-Small Cell Lung Cancer: Real-World Effectiveness Versus Trial Efficacy.. Clinical trial efficacy and real-world effect...,cooccurrence,0.7,e8
PR,lung cancer,biomarker_cancer_cooccurrence,Co-occurrence in text: Pembrolizumab Plus Chemotherapy Per PD-L1 Stratum In Patients With Metastatic Non-Small Cell Lung Cancer: Real-World Effectiveness Versus Trial Efficacy.. Clinical trial efficacy and real-world effect...,cooccurrence,0.7,e9
PR,non-small cell lung cancer,biomarker_cancer_cooccurrence,Co-occurrence in text: Pembrolizumab Plus Chemotherapy Per PD-L1 Stratum In Patients With Metastatic Non-Small Cell Lung Cancer: Real-World Effectiveness Versus Trial Efficacy.. Clinical trial efficacy and real-world effect...,cooccurrence,0.7,e10
pembrolizumab,ALK,drug_gene_cooccurrence,"Co-occurrence in text: PD-L1 expression guidance on sintilimab versus pembrolizumab with or without platinum-doublet chemotherapy in untreated patients with advanced non-small cell lung cancer (CTONG1901): A phase 2, random...",cooccurrence,0.6,e11
pembrolizumab,EGFR,drug_gene_cooccurrence,"Co-occurrence in text: PD-L1 expression guidance on sintilimab versus pembrolizumab with or without platinum-doublet chemotherapy in untreated patients with advanced non-small cell lung cancer (CTONG1901): A phase 2, random...",cooccurrence,0.6,e12
ALK,lung cancer,biomarker_cancer_cooccurrence,"Co-occurrence in text: PD-L1 expression guidance on sintilimab versus pembrolizumab with or without platinum-doublet chemotherapy in untreated patients with advanced non-small cell lung cancer (CTONG1901): A phase 2, random...",cooccurrence,0.7,e13
ALK,non-small cell lung cancer,biomarker_cancer_cooccurrence,"Co-occurrence in text: PD-L1 expression guidance on sintilimab versus pembrolizumab with or without platinum-doublet chemotherapy in untreated patients with advanced non-small cell lung cancer (CTONG1901): A phase 2, random...",cooccurrence,0.7,e14
EGFR,lung cancer,biomarker_cancer_cooccurrence,"Co-occurrence in text: PD-L1 expression guidance on sintilimab versus pembrolizumab with or without platinum-doublet chemotherapy in untreated patients with advanced non-small cell lung cancer (CTONG1901): A phase 2, random...",cooccurrence,0.7,e15
EGFR,non-small cell lung cancer,biomarker_cancer_cooccurrence,"Co-occurrence in text: PD-L1 expression guidance on sintilimab versus pembrolizumab with or without platinum-doublet chemotherapy in untreated patients with advanced non-small cell lung cancer (CTONG1901): A phase 2, random...",cooccurrence,0.7,e16
RET,lung cancer,biomarker_cancer_cooccurrence,Co-occurrence in text: Clinical significance of antinuclear antibody as prognostic marker for first-line pembrolizumab in advanced non-small cell lung cancer.. The relationship between antinuclear antibody (ANA) and the eff...,cooccurrence,0.7,e17
RET,non-small cell lung cancer,biomarker_cancer_cooccurrence,Co-occurrence in text: Clinical significance of antinuclear antibody as prognostic marker for first-line pembrolizumab in advanced non-small cell lung cancer.. The relationship between antinuclear antibody (ANA) and the eff...,cooccurrence,0.7,e18
nivolumab,MET,drug_gene_cooccurrence,Co-occurrence in text: Comparison of the Efficacy and Safety of Perioperative Immunochemotherapeutic Strategies for Resectable Non-small Cell Lung Cancer: a Systematic Review and Network Meta-analysis.. The aim of this netw...,cooccurrence,0.6,e19
nivolumab,pembrolizumab,drug_drug_cooccurrence,"Co-occurrence in text: Soluble PD-L1 changes in advanced non-small cell lung cancer patients treated with PD-1 inhibitors: an individual patient data meta-analysis.. Currently, first-line immune checkpoint inhibitors (ICIs)...",cooccurrence,0.5,e20
pembrolizumab,HER2,drug_gene_cooccurrence,Co-occurrence in text: Stage 4 Non-small Cell Lung Cancer With Human Epidermal Growth Factor Receptor 2 Alterations and Myocarditis Induced by Immune Checkpoint Inhibitors: A Case Report.. Immune checkpoint inhibitor (ICI)-...,cooccurrence,0.6,e21
AR,esophageal cancer,biomarker_cancer_cooccurrence,Co-occurrence in text: Stage 4 Non-small Cell Lung Cancer With Human Epidermal Growth Factor Receptor 2 Alterations and Myocarditis Induced by Immune Checkpoint Inhibitors: A Case Report.. Immune checkpoint inhibitor (ICI)-...,cooccurrence,0.7,e22
ER,esophageal cancer,biomarker_cancer_cooccurrence,Co-occurrence in text: Stage 4 Non-small Cell Lung Cancer With Human Epidermal Growth Factor Receptor 2 Alterations and Myocarditis Induced by Immune Checkpoint Inhibitors: A Case Report.. Immune checkpoint inhibitor (ICI)-...,cooccurrence,0.7,e23
HER2,esophageal cancer,biomarker_cancer_cooccurrence,Co-occurrence in text: Stage 4 Non-small Cell Lung Cancer With Human Epidermal Growth Factor Receptor 2 Alterations and Myocarditis Induced by Immune Checkpoint Inhibitors: A Case Report.. Immune checkpoint inhibitor (ICI)-...,cooccurrence,0.7,e24
HER2,lung cancer,biomarker_cancer_cooccurrence,Co-occurrence in text: Stage 4 Non-small Cell Lung Cancer With Human Epidermal Growth Factor Receptor 2 Alterations and Myocarditis Induced by Immune Checkpoint Inhibitors: A Case Report.. Immune checkpoint inhibitor (ICI)-...,cooccurrence,0.7,e25
HER2,non-small cell lung cancer,biomarker_cancer_cooccurrence,Co-occurrence in text: Stage 4 Non-small Cell Lung Cancer With Human Epidermal Growth Factor Receptor 2 Alterations and Myocarditis Induced by Immune Checkpoint Inhibitors: A Case Report.. Immune checkpoint inhibitor (ICI)-...,cooccurrence,0.7,e26
MET,esophageal cancer,biomarker_cancer_cooccurrence,Co-occurrence in text: Stage 4 Non-small Cell Lung Cancer With Human Epidermal Growth Factor Receptor 2 Alterations and Myocarditis Induced by Immune Checkpoint Inhibitors: A Case Report.. Immune checkpoint inhibitor (ICI)-...,cooccurrence,0.7,e27
PD-L1,esophageal cancer,biomarker_cancer_cooccurrence,Co-occurrence in text: Stage 4 Non-small Cell Lung Cancer With Human Epidermal Growth Factor Receptor 2 Alterations and Myocarditis Induced by Immune Checkpoint Inhibitors: A Case Report.. Immune checkpoint inhibitor (ICI)-...,cooccurrence,0.7,e28
PR,esophageal cancer,biomarker_cancer_cooccurrence,Co-occurrence in text: Stage 4 Non-small Cell Lung Cancer With Human Epidermal Growth Factor Receptor 2 Alterations and Myocarditis Induced by Immune Checkpoint Inhibitors: A Case Report.. Immune checkpoint inhibitor (ICI)-...,cooccurrence,0.7,e29
ipilimumab,nivolumab,drug_drug_cooccurrence,Co-occurrence in text: Improving visual acuity with nivolumab plus ipilimumab plus two cycles of chemotherapy following a diagnosis of lung adenocarcinoma with choroidal metastasis: A case report and literature review.. A 7...,cooccurrence,0.5,e30
ipilimumab,EGFR,drug_gene_cooccurrence,Co-occurrence in text: Improving visual acuity with nivolumab plus ipilimumab plus two cycles of chemotherapy following a diagnosis of lung adenocarcinoma with choroidal metastasis: A case report and literature review.. A 7...,cooccurrence,0.6,e31
ipilimumab,MET,drug_gene_cooccurrence,Co-occurrence in text: Improving visual acuity with nivolumab plus ipilimumab plus two cycles of chemotherapy following a diagnosis of lung adenocarcinoma with choroidal metastasis: A case report and literature review.. A 7...,cooccurrence,0.6,e32
nivolumab,EGFR,drug_gene_cooccurrence,Co-occurrence in text: Improving visual acuity with nivolumab plus ipilimumab plus two cycles of chemotherapy following a diagnosis of lung adenocarcinoma with choroidal metastasis: A case report and literature review.. A 7...,cooccurrence,0.6,e33
ipilimumab,ALK,drug_gene_cooccurrence,"Co-occurrence in text: Nivolumab plus chemotherapy in first-line metastatic non-small-cell lung cancer: results of the phase III CheckMate 227 Part 2 trial.. In CheckMate 227 Part 1, first-line nivolumab plus ipilimumab pro...",cooccurrence,0.6,e34
ipilimumab,TP53,drug_gene_cooccurrence,"Co-occurrence in text: Nivolumab plus chemotherapy in first-line metastatic non-small-cell lung cancer: results of the phase III CheckMate 227 Part 2 trial.. In CheckMate 227 Part 1, first-line nivolumab plus ipilimumab pro...",cooccurrence,0.6,e35
nivolumab,ALK,drug_gene_cooccurrence,"Co-occurrence in text: Nivolumab plus chemotherapy in first-line metastatic non-small-cell lung cancer: results of the phase III CheckMate 227 Part 2 trial.. In CheckMate 227 Part 1, first-line nivolumab plus ipilimumab pro...",cooccurrence,0.6,e36
nivolumab,TP53,drug_gene_cooccurrence,"Co-occurrence in text: Nivolumab plus chemotherapy in first-line metastatic non-small-cell lung cancer: results of the phase III CheckMate 227 Part 2 trial.. In CheckMate 227 Part 1, first-line nivolumab plus ipilimumab pro...",cooccurrence,0.6,e37
TP53,lung cancer,biomarker_cancer_cooccurrence,"Co-occurrence in text: Nivolumab plus chemotherapy in first-line metastatic non-small-cell lung cancer: results of the phase III CheckMate 227 Part 2 trial.. In CheckMate 227 Part 1, first-line nivolumab plus ipilimumab pro...",cooccurrence,0.7,e38
pembrolizumab,TP53,drug_gene_cooccurrence,Co-occurrence in text: Pembrolizumab combined with anlotinib improves therapeutic efficacy in pulmonary sarcomatoid carcinoma with TMB-H and PD-L1 expression: a case report and literature review.. Pulmonary sarcomatoid carc...,cooccurrence,0.6,e39
TMB,lung cancer,biomarker_cancer_cooccurrence,Co-occurrence in text: Pembrolizumab combined with anlotinib improves therapeutic efficacy in pulmonary sarcomatoid carcinoma with TMB-H and PD-L1 expression: a case report and literature review.. Pulmonary sarcomatoid carc...,cooccurrence,0.7,e40
TMB,non-small cell lung cancer,biomarker_cancer_cooccurrence,Co-occurrence in text: Pembrolizumab combined with anlotinib improves therapeutic efficacy in pulmonary sarcomatoid carcinoma with TMB-H and PD-L1 expression: a case report and literature review.. Pulmonary sarcomatoid carc...,cooccurrence,0.7,e41
TP53,non-small cell lung cancer,biomarker_cancer_cooccurrence,Co-occurrence in text: Pembrolizumab combined with anlotinib improves therapeutic efficacy in pulmonary sarcomatoid carcinoma with TMB-H and PD-L1 expression: a case report and literature review.. Pulmonary sarcomatoid carc...,cooccurrence,0.7,e42
atezolizumab,ipilimumab,drug_drug_cooccurrence,Co-occurrence in text: Cost-effectiveness of first-line immunotherapy for advanced non-small cell lung cancer with different PD-L1 expression levels: A comprehensive overview.. Immunotherapies can substantially improve trea...,cooccurrence,0.5,e43
atezolizumab,nivolumab,drug_drug_cooccurrence,Co-occurrence in text: Cost-effectiveness of first-line immunotherapy for advanced non-small cell lung cancer with different PD-L1 expression levels: A comprehensive overview.. Immunotherapies can substantially improve trea...,cooccurrence,0.5,e44
atezolizumab,pembrolizumab,drug_drug_cooccurrence,Co-occurrence in text: Cost-effectiveness of first-line immunotherapy for advanced non-small cell lung cancer with different PD-L1 expression levels: A comprehensive overview.. Immunotherapies can substantially improve trea...,cooccurrence,0.5,e45
ipilimumab,pembrolizumab,drug_drug_cooccurrence,Co-occurrence in text: Cost-effectiveness of first-line immunotherapy for advanced non-small cell lung cancer with different PD-L1 expression levels: A comprehensive overview.. Immunotherapies can substantially improve trea...,cooccurrence,0.5,e46
atezolizumab,MET,drug_gene_cooccurrence,Co-occurrence in text: Comparison of the profiles of first-line PD-1/PD-L1 inhibitors for advanced NSCLC lacking driver gene mutations: a systematic review and Bayesian network meta-analysis.. Numerous first-line immune che...,cooccurrence,0.6,e47
carboplatin,cisplatin,drug_drug_cooccurrence,Co-occurrence in text: Multi-Center Real-World Outcomes of Nivolumab Plus Ipilimumab and Chemotherapy in Patients with Metastatic Non-Small-Cell Lung Cancer.. Immune checkpoint inhibitors have become the standard of care in...,cooccurrence,0.5,e48
carboplatin,ipilimumab,drug_drug_cooccurrence,Co-occurrence in text: Multi-Center Real-World Outcomes of Nivolumab Plus Ipilimumab and Chemotherapy in Patients with Metastatic Non-Small-Cell Lung Cancer.. Immune checkpoint inhibitors have become the standard of care in...,cooccurrence,0.5,e49
carboplatin,nivolumab,drug_drug_cooccurrence,Co-occurrence in text: Multi-Center Real-World Outcomes of Nivolumab Plus Ipilimumab and Chemotherapy in Patients with Metastatic Non-Small-Cell Lung Cancer.. Immune checkpoint inhibitors have become the standard of care in...,cooccurrence,0.5,e50
carboplatin,paclitaxel,drug_drug_cooccurrence,Co-occurrence in text: Multi-Center Real-World Outcomes of Nivolumab Plus Ipilimumab and Chemotherapy in Patients with Metastatic Non-Small-Cell Lung Cancer.. Immune checkpoint inhibitors have become the standard of care in...,cooccurrence,0.5,e51
cisplatin,ipilimumab,drug_drug_cooccurrence,Co-occurrence in text: Multi-Center Real-World Outcomes of Nivolumab Plus Ipilimumab and Chemotherapy in Patients with Metastatic Non-Small-Cell Lung Cancer.. Immune checkpoint inhibitors have become the standard of care in...,cooccurrence,0.5,e52
cisplatin,nivolumab,drug_drug_cooccurrence,Co-occurrence in text: Multi-Center Real-World Outcomes of Nivolumab Plus Ipilimumab and Chemotherapy in Patients with Metastatic Non-Small-Cell Lung Cancer.. Immune checkpoint inhibitors have become the standard of care in...,cooccurrence,0.5,e53
cisplatin,paclitaxel,drug_drug_cooccurrence,Co-occurrence in text: Multi-Center Real-World Outcomes of Nivolumab Plus Ipilimumab and Chemotherapy in Patients with Metastatic Non-Small-Cell Lung Cancer.. Immune checkpoint inhibitors have become the standard of care in...,cooccurrence,0.5,e54
ipilimumab,paclitaxel,drug_drug_cooccurrence,Co-occurrence in text: Multi-Center Real-World Outcomes of Nivolumab Plus Ipilimumab and Chemotherapy in Patients with Metastatic Non-Small-Cell Lung Cancer.. Immune checkpoint inhibitors have become the standard of care in...,cooccurrence,0.5,e55
nivolumab,paclitaxel,drug_drug_cooccurrence,Co-occurrence in text: Multi-Center Real-World Outcomes of Nivolumab Plus Ipilimumab and Chemotherapy in Patients with Metastatic Non-Small-Cell Lung Cancer.. Immune checkpoint inhibitors have become the standard of care in...,cooccurrence,0.5,e56
carboplatin,MET,drug_gene_cooccurrence,Co-occurrence in text: Multi-Center Real-World Outcomes of Nivolumab Plus Ipilimumab and Chemotherapy in Patients with Metastatic Non-Small-Cell Lung Cancer.. Immune checkpoint inhibitors have become the standard of care in...,cooccurrence,0.6,e57
cisplatin,MET,drug_gene_cooccurrence,Co-occurrence in text: Multi-Center Real-World Outcomes of Nivolumab Plus Ipilimumab and Chemotherapy in Patients with Metastatic Non-Small-Cell Lung Cancer.. Immune checkpoint inhibitors have become the standard of care in...,cooccurrence,0.6,e58
paclitaxel,MET,drug_gene_cooccurrence,Co-occurrence in text: Multi-Center Real-World Outcomes of Nivolumab Plus Ipilimumab and Chemotherapy in Patients with Metastatic Non-Small-Cell Lung Cancer.. Immune checkpoint inhibitors have become the standard of care in...,cooccurrence,0.6,e59
cyclophosphamide,nivolumab,drug_drug_cooccurrence,Co-occurrence in text: Nivolumab after Induction Chemotherapy in Previously Treated Non-Small-Cell Lung Cancer Patients with Low PD-L1 Expression.. This study aimed to investigate whether cyclophosphamide (C) and adriamycin...,cooccurrence,0.5,e60
cyclophosphamide,MYC,drug_gene_cooccurrence,Co-occurrence in text: Nivolumab after Induction Chemotherapy in Previously Treated Non-Small-Cell Lung Cancer Patients with Low PD-L1 Expression.. This study aimed to investigate whether cyclophosphamide (C) and adriamycin...,cooccurrence,0.6,e61
nivolumab,MYC,drug_gene_cooccurrence,Co-occurrence in text: Nivolumab after Induction Chemotherapy in Previously Treated Non-Small-Cell Lung Cancer Patients with Low PD-L1 Expression.. This study aimed to investigate whether cyclophosphamide (C) and adriamycin...,cooccurrence,0.6,e62
AR,breast cancer,biomarker_cancer_cooccurrence,"Co-occurrence in text: Cancer cell-intrinsic PD-1: Its role in malignant progression and immunotherapy.. Programmed cell death protein-1 (PD-1), also called CD279, is coded by the PDCD1 gene and is constitutively expressed ...",cooccurrence,0.7,e63
AR,glioblastoma,biomarker_cancer_cooccurrence,"Co-occurrence in text: Cancer cell-intrinsic PD-1: Its role in malignant progression and immunotherapy.. Programmed cell death protein-1 (PD-1), also called CD279, is coded by the PDCD1 gene and is constitutively expressed ...",cooccurrence,0.7,e64
AR,hepatocellular carcinoma,biomarker_cancer_cooccurrence,"Co-occurrence in text: Cancer cell-intrinsic PD-1: Its role in malignant progression and immunotherapy.. Programmed cell death protein-1 (PD-1), also called CD279, is coded by the PDCD1 gene and is constitutively expressed ...",cooccurrence,0.7,e65
AR,melanoma,biomarker_cancer_cooccurrence,"Co-occurrence in text: Cancer cell-intrinsic PD-1: Its role in malignant progression and immunotherapy.. Programmed cell death protein-1 (PD-1), also called CD279, is coded by the PDCD1 gene and is constitutively expressed ...",cooccurrence,0.7,e66
AR,triple-negative breast cancer,biomarker_cancer_cooccurrence,"Co-occurrence in text: Cancer cell-intrinsic PD-1: Its role in malignant progression and immunotherapy.. Programmed cell death protein-1 (PD-1), also called CD279, is coded by the PDCD1 gene and is constitutively expressed ...",cooccurrence,0.7,e67
ER,breast cancer,biomarker_cancer_cooccurrence,"Co-occurrence in text: Cancer cell-intrinsic PD-1: Its role in malignant progression and immunotherapy.. Programmed cell death protein-1 (PD-1), also called CD279, is coded by the PDCD1 gene and is constitutively expressed ...",cooccurrence,0.7,e68
ER,glioblastoma,biomarker_cancer_cooccurrence,"Co-occurrence in text: Cancer cell-intrinsic PD-1: Its role in malignant progression and immunotherapy.. Programmed cell death protein-1 (PD-1), also called CD279, is coded by the PDCD1 gene and is constitutively expressed ...",cooccurrence,0.7,e69
ER,hepatocellular carcinoma,biomarker_cancer_cooccurrence,"Co-occurrence in text: Cancer cell-intrinsic PD-1: Its role in malignant progression and immunotherapy.. Programmed cell death protein-1 (PD-1), also called CD279, is coded by the PDCD1 gene and is constitutively expressed ...",cooccurrence,0.7,e70
ER,melanoma,biomarker_cancer_cooccurrence,"Co-occurrence in text: Cancer cell-intrinsic PD-1: Its role in malignant progression and immunotherapy.. Programmed cell death protein-1 (PD-1), also called CD279, is coded by the PDCD1 gene and is constitutively expressed ...",cooccurrence,0.7,e71
ER,triple-negative breast cancer,biomarker_cancer_cooccurrence,"Co-occurrence in text: Cancer cell-intrinsic PD-1: Its role in malignant progression and immunotherapy.. Programmed cell death protein-1 (PD-1), also called CD279, is coded by the PDCD1 gene and is constitutively expressed ...",cooccurrence,0.7,e72
MET,breast cancer,biomarker_cancer_cooccurrence,"Co-occurrence in text: Cancer cell-intrinsic PD-1: Its role in malignant progression and immunotherapy.. Programmed cell death protein-1 (PD-1), also called CD279, is coded by the PDCD1 gene and is constitutively expressed ...",cooccurrence,0.7,e73
MET,glioblastoma,biomarker_cancer_cooccurrence,"Co-occurrence in text: Cancer cell-intrinsic PD-1: Its role in malignant progression and immunotherapy.. Programmed cell death protein-1 (PD-1), also called CD279, is coded by the PDCD1 gene and is constitutively expressed ...",cooccurrence,0.7,e74
MET,hepatocellular carcinoma,biomarker_cancer_cooccurrence,"Co-occurrence in text: Cancer cell-intrinsic PD-1: Its role in malignant progression and immunotherapy.. Programmed cell death protein-1 (PD-1), also called CD279, is coded by the PDCD1 gene and is constitutively expressed ...",cooccurrence,0.7,e75
MET,melanoma,biomarker_cancer_cooccurrence,"Co-occurrence in text: Cancer cell-intrinsic PD-1: Its role in malignant progression and immunotherapy.. Programmed cell death protein-1 (PD-1), also called CD279, is coded by the PDCD1 gene and is constitutively expressed ...",cooccurrence,0.7,e76
MET,triple-negative breast cancer,biomarker_cancer_cooccurrence,"Co-occurrence in text: Cancer cell-intrinsic PD-1: Its role in malignant progression and immunotherapy.. Programmed cell death protein-1 (PD-1), also called CD279, is coded by the PDCD1 gene and is constitutively expressed ...",cooccurrence,0.7,e77
PD-L1,breast cancer,biomarker_cancer_cooccurrence,"Co-occurrence in text: Cancer cell-intrinsic PD-1: Its role in malignant progression and immunotherapy.. Programmed cell death protein-1 (PD-1), also called CD279, is coded by the PDCD1 gene and is constitutively expressed ...",cooccurrence,0.7,e78
PD-L1,glioblastoma,biomarker_cancer_cooccurrence,"Co-occurrence in text: Cancer cell-intrinsic PD-1: Its role in malignant progression and immunotherapy.. Programmed cell death protein-1 (PD-1), also called CD279, is coded by the PDCD1 gene and is constitutively expressed ...",cooccurrence,0.7,e79
PD-L1,hepatocellular carcinoma,biomarker_cancer_cooccurrence,"Co-occurrence in text: Cancer cell-intrinsic PD-1: Its role in malignant progression and immunotherapy.. Programmed cell death protein-1 (PD-1), also called CD279, is coded by the PDCD1 gene and is constitutively expressed ...",cooccurrence,0.7,e80
PD-L1,melanoma,biomarker_cancer_cooccurrence,"Co-occurrence in text: Cancer cell-intrinsic PD-1: Its role in malignant progression and immunotherapy.. Programmed cell death protein-1 (PD-1), also called CD279, is coded by the PDCD1 gene and is constitutively expressed ...",cooccurrence,0.7,e81
PD-L1,triple-negative breast cancer,biomarker_cancer_cooccurrence,"Co-occurrence in text: Cancer cell-intrinsic PD-1: Its role in malignant progression and immunotherapy.. Programmed cell death protein-1 (PD-1), also called CD279, is coded by the PDCD1 gene and is constitutively expressed ...",cooccurrence,0.7,e82
PR,breast cancer,biomarker_cancer_cooccurrence,"Co-occurrence in text: Cancer cell-intrinsic PD-1: Its role in malignant progression and immunotherapy.. Programmed cell death protein-1 (PD-1), also called CD279, is coded by the PDCD1 gene and is constitutively expressed ...",cooccurrence,0.7,e83
PR,glioblastoma,biomarker_cancer_cooccurrence,"Co-occurrence in text: Cancer cell-intrinsic PD-1: Its role in malignant progression and immunotherapy.. Programmed cell death protein-1 (PD-1), also called CD279, is coded by the PDCD1 gene and is constitutively expressed ...",cooccurrence,0.7,e84
PR,hepatocellular carcinoma,biomarker_cancer_cooccurrence,"Co-occurrence in text: Cancer cell-intrinsic PD-1: Its role in malignant progression and immunotherapy.. Programmed cell death protein-1 (PD-1), also called CD279, is coded by the PDCD1 gene and is constitutively expressed ...",cooccurrence,0.7,e85
PR,melanoma,biomarker_cancer_cooccurrence,"Co-occurrence in text: Cancer cell-intrinsic PD-1: Its role in malignant progression and immunotherapy.. Programmed cell death protein-1 (PD-1), also called CD279, is coded by the PDCD1 gene and is constitutively expressed ...",cooccurrence,0.7,e86
PR,triple-negative breast cancer,biomarker_cancer_cooccurrence,"Co-occurrence in text: Cancer cell-intrinsic PD-1: Its role in malignant progression and immunotherapy.. Programmed cell death protein-1 (PD-1), also called CD279, is coded by the PDCD1 gene and is constitutively expressed ...",cooccurrence,0.7,e87
atezolizumab,docetaxel,drug_drug_cooccurrence,Co-occurrence in text: Efficacy and safety of immune checkpoint inhibitors for advanced non-small cell lung cancer with or without PD-L1 selection: A systematic review and network meta-analysis.. Immune checkpoint inhibitor...,cooccurrence,0.5,e88
docetaxel,pembrolizumab,drug_drug_cooccurrence,Co-occurrence in text: Efficacy and safety of immune checkpoint inhibitors for advanced non-small cell lung cancer with or without PD-L1 selection: A systematic review and network meta-analysis.. Immune checkpoint inhibitor...,cooccurrence,0.5,e89
docetaxel,MET,drug_gene_cooccurrence,Co-occurrence in text: Efficacy and safety of immune checkpoint inhibitors for advanced non-small cell lung cancer with or without PD-L1 selection: A systematic review and network meta-analysis.. Immune checkpoint inhibitor...,cooccurrence,0.6,e90
docetaxel,nivolumab,drug_drug_cooccurrence,"Co-occurrence in text: Durable Response to Maintenance Treatment Comprised of Viagenpumatucel-L, Nivolumab, Ramucirumab, and Docetaxel in a PD-L1-Low Advanced-Stage Non-Small-Cell Lung Cancer: A Case Report.. Checkpoint inh...",cooccurrence,0.5,e91
letrozole,pembrolizumab,drug_drug_cooccurrence,Co-occurrence in text: Autocrine 17-β-Estradiol/Estrogen Receptor-α Loop Determines the Response to Immune Checkpoint Inhibitors in Non-Small Cell Lung Cancer.. The response to immune checkpoint inhibitors (ICI) often diffe...,cooccurrence,0.5,e92
letrozole,EGFR,drug_gene_cooccurrence,Co-occurrence in text: Autocrine 17-β-Estradiol/Estrogen Receptor-α Loop Determines the Response to Immune Checkpoint Inhibitors in Non-Small Cell Lung Cancer.. The response to immune checkpoint inhibitors (ICI) often diffe...,cooccurrence,0.6,e93
letrozole,MET,drug_gene_cooccurrence,Co-occurrence in text: Autocrine 17-β-Estradiol/Estrogen Receptor-α Loop Determines the Response to Immune Checkpoint Inhibitors in Non-Small Cell Lung Cancer.. The response to immune checkpoint inhibitors (ICI) often diffe...,cooccurrence,0.6,e94
AR,bladder cancer,biomarker_cancer_cooccurrence,Co-occurrence in text: Assessment of Tumor Mutational Burden and Outcomes in Patients With Diverse Advanced Cancers Treated With Immunotherapy.. There are few studies assessing the association of tumor mutational burden (TM...,cooccurrence,0.7,e95
ER,bladder cancer,biomarker_cancer_cooccurrence,Co-occurrence in text: Assessment of Tumor Mutational Burden and Outcomes in Patients With Diverse Advanced Cancers Treated With Immunotherapy.. There are few studies assessing the association of tumor mutational burden (TM...,cooccurrence,0.7,e96
PD-L1,bladder cancer,biomarker_cancer_cooccurrence,Co-occurrence in text: Assessment of Tumor Mutational Burden and Outcomes in Patients With Diverse Advanced Cancers Treated With Immunotherapy.. There are few studies assessing the association of tumor mutational burden (TM...,cooccurrence,0.7,e97
PR,bladder cancer,biomarker_cancer_cooccurrence,Co-occurrence in text: Assessment of Tumor Mutational Burden and Outcomes in Patients With Diverse Advanced Cancers Treated With Immunotherapy.. There are few studies assessing the association of tumor mutational burden (TM...,cooccurrence,0.7,e98
RET,bladder cancer,biomarker_cancer_cooccurrence,Co-occurrence in text: Assessment of Tumor Mutational Burden and Outcomes in Patients With Diverse Advanced Cancers Treated With Immunotherapy.. There are few studies assessing the association of tumor mutational burden (TM...,cooccurrence,0.7,e99
TMB,bladder cancer,biomarker_cancer_cooccurrence,Co-occurrence in text: Assessment of Tumor Mutational Burden and Outcomes in Patients With Diverse Advanced Cancers Treated With Immunotherapy.. There are few studies assessing the association of tumor mutational burden (TM...,cooccurrence,0.7,e100
PR,lymphoma,biomarker_cancer_cooccurrence,Co-occurrence in text: Case report: anaplastic lymphoma kinase (. The presence of anaplastic lymphoma kinase (...,cooccurrence,0.7,e101
atezolizumab,cisplatin,drug_drug_cooccurrence,Co-occurrence in text: Immune checkpoint inhibitors modulate the cytotoxic effect of chemotherapy in lung adenocarcinoma cells.. Immunotherapy using immune checkpoint inhibitors (ICIs) has significantly improved survival in...,cooccurrence,0.5,e102
atezolizumab,paclitaxel,drug_drug_cooccurrence,Co-occurrence in text: Immune checkpoint inhibitors modulate the cytotoxic effect of chemotherapy in lung adenocarcinoma cells.. Immunotherapy using immune checkpoint inhibitors (ICIs) has significantly improved survival in...,cooccurrence,0.5,e103
cisplatin,docetaxel,drug_drug_cooccurrence,Co-occurrence in text: Immune checkpoint inhibitors modulate the cytotoxic effect of chemotherapy in lung adenocarcinoma cells.. Immunotherapy using immune checkpoint inhibitors (ICIs) has significantly improved survival in...,cooccurrence,0.5,e104
cisplatin,pembrolizumab,drug_drug_cooccurrence,Co-occurrence in text: Immune checkpoint inhibitors modulate the cytotoxic effect of chemotherapy in lung adenocarcinoma cells.. Immunotherapy using immune checkpoint inhibitors (ICIs) has significantly improved survival in...,cooccurrence,0.5,e105
docetaxel,paclitaxel,drug_drug_cooccurrence,Co-occurrence in text: Immune checkpoint inhibitors modulate the cytotoxic effect of chemotherapy in lung adenocarcinoma cells.. Immunotherapy using immune checkpoint inhibitors (ICIs) has significantly improved survival in...,cooccurrence,0.5,e106
paclitaxel,pembrolizumab,drug_drug_cooccurrence,Co-occurrence in text: Immune checkpoint inhibitors modulate the cytotoxic effect of chemotherapy in lung adenocarcinoma cells.. Immunotherapy using immune checkpoint inhibitors (ICIs) has significantly improved survival in...,cooccurrence,0.5,e107
carboplatin,pembrolizumab,drug_drug_cooccurrence,Co-occurrence in text: Pembrolizumab plus pemetrexed-carboplatin combination in first-line treatment of advanced non-squamous non-small cell lung cancer: a multicenter real-life study (CAP29).. Pembrolizumab combined with c...,cooccurrence,0.5,e108
AR,renal cell carcinoma,biomarker_cancer_cooccurrence,Co-occurrence in text: Differential treatment responses to immune checkpoint inhibitor (ICI) therapy in a case of multiple primary malignancies: the programmed death ligand-1 (PD-L1) negative ureteral and lung metastasis fr...,cooccurrence,0.7,e109
ER,renal cell carcinoma,biomarker_cancer_cooccurrence,Co-occurrence in text: Differential treatment responses to immune checkpoint inhibitor (ICI) therapy in a case of multiple primary malignancies: the programmed death ligand-1 (PD-L1) negative ureteral and lung metastasis fr...,cooccurrence,0.7,e110
MET,renal cell carcinoma,biomarker_cancer_cooccurrence,Co-occurrence in text: Differential treatment responses to immune checkpoint inhibitor (ICI) therapy in a case of multiple primary malignancies: the programmed death ligand-1 (PD-L1) negative ureteral and lung metastasis fr...,cooccurrence,0.7,e111
PD-L1,renal cell carcinoma,biomarker_cancer_cooccurrence,Co-occurrence in text: Differential treatment responses to immune checkpoint inhibitor (ICI) therapy in a case of multiple primary malignancies: the programmed death ligand-1 (PD-L1) negative ureteral and lung metastasis fr...,cooccurrence,0.7,e112
PR,renal cell carcinoma,biomarker_cancer_cooccurrence,Co-occurrence in text: Differential treatment responses to immune checkpoint inhibitor (ICI) therapy in a case of multiple primary malignancies: the programmed death ligand-1 (PD-L1) negative ureteral and lung metastasis fr...,cooccurrence,0.7,e113
RET,renal cell carcinoma,biomarker_cancer_cooccurrence,Co-occurrence in text: Differential treatment responses to immune checkpoint inhibitor (ICI) therapy in a case of multiple primary malignancies: the programmed death ligand-1 (PD-L1) negative ureteral and lung metastasis fr...,cooccurrence,0.7,e114
docetaxel,ALK,drug_gene_cooccurrence,Co-occurrence in text: Study protocol of KeyPemls-004: A phase 2 study of pembrolizumab in combination with plinabulin and docetaxel in previously treated patients with metastatic non-small cell lung cancer and progressive ...,cooccurrence,0.6,e115
docetaxel,EGFR,drug_gene_cooccurrence,Co-occurrence in text: Study protocol of KeyPemls-004: A phase 2 study of pembrolizumab in combination with plinabulin and docetaxel in previously treated patients with metastatic non-small cell lung cancer and progressive ...,cooccurrence,0.6,e116
ALK,lymphoma,biomarker_cancer_cooccurrence,Co-occurrence in text: Study protocol of KeyPemls-004: A phase 2 study of pembrolizumab in combination with plinabulin and docetaxel in previously treated patients with metastatic non-small cell lung cancer and progressive ...,cooccurrence,0.7,e117
AR,lymphoma,biomarker_cancer_cooccurrence,Co-occurrence in text: Study protocol of KeyPemls-004: A phase 2 study of pembrolizumab in combination with plinabulin and docetaxel in previously treated patients with metastatic non-small cell lung cancer and progressive ...,cooccurrence,0.7,e118
EGFR,lymphoma,biomarker_cancer_cooccurrence,Co-occurrence in text: Study protocol of KeyPemls-004: A phase 2 study of pembrolizumab in combination with plinabulin and docetaxel in previously treated patients with metastatic non-small cell lung cancer and progressive ...,cooccurrence,0.7,e119
ER,lymphoma,biomarker_cancer_cooccurrence,Co-occurrence in text: Study protocol of KeyPemls-004: A phase 2 study of pembrolizumab in combination with plinabulin and docetaxel in previously treated patients with metastatic non-small cell lung cancer and progressive ...,cooccurrence,0.7,e120
MET,lymphoma,biomarker_cancer_cooccurrence,Co-occurrence in text: Study protocol of KeyPemls-004: A phase 2 study of pembrolizumab in combination with plinabulin and docetaxel in previously treated patients with metastatic non-small cell lung cancer and progressive ...,cooccurrence,0.7,e121
PD-L1,lymphoma,biomarker_cancer_cooccurrence,Co-occurrence in text: Study protocol of KeyPemls-004: A phase 2 study of pembrolizumab in combination with plinabulin and docetaxel in previously treated patients with metastatic non-small cell lung cancer and progressive ...,cooccurrence,0.7,e122
pembrolizumab,KRAS,drug_gene_cooccurrence,Co-occurrence in text: Associations of tissue tumor mutational burden and mutational status with clinical outcomes in KEYNOTE-042: pembrolizumab versus chemotherapy for advanced PD-L1-positive NSCLC.. We evaluated whether t...,cooccurrence,0.6,e123
KRAS,lung cancer,biomarker_cancer_cooccurrence,Co-occurrence in text: Associations of tissue tumor mutational burden and mutational status with clinical outcomes in KEYNOTE-042: pembrolizumab versus chemotherapy for advanced PD-L1-positive NSCLC.. We evaluated whether t...,cooccurrence,0.7,e124
atezolizumab,ALK,drug_gene_cooccurrence,Co-occurrence in text: Cost-effectiveness of atezolizumab versus pembrolizumab as first-line treatment in PD-L1-positive advanced non-small-cell lung cancer in Spain.. Atezolizumab has recently been approved for first-line ...,cooccurrence,0.6,e125
atezolizumab,EGFR,drug_gene_cooccurrence,Co-occurrence in text: Cost-effectiveness of atezolizumab versus pembrolizumab as first-line treatment in PD-L1-positive advanced non-small-cell lung cancer in Spain.. Atezolizumab has recently been approved for first-line ...,cooccurrence,0.6,e126
HER2,breast cancer,biomarker_cancer_cooccurrence,"Co-occurrence in text: Combination of chemotherapeutic agents and biological response modifiers (immunotherapy) in triple-negative/Her2( +) breast cancer, multiple myeloma, and non-small-cell lung cancer.. Biological respon...",cooccurrence,0.7,e127
AR,gastric cancer,biomarker_cancer_cooccurrence,"Co-occurrence in text: Initial Therapeutic Approach with Pembrolizumab in Synchronous Multiple Cancers, Including Non-Small Cell Lung Cancer, Highly Positive for Programmed Death-Ligand 1 Expression.. Treatment of synchrono...",cooccurrence,0.7,e128
ER,gastric cancer,biomarker_cancer_cooccurrence,"Co-occurrence in text: Initial Therapeutic Approach with Pembrolizumab in Synchronous Multiple Cancers, Including Non-Small Cell Lung Cancer, Highly Positive for Programmed Death-Ligand 1 Expression.. Treatment of synchrono...",cooccurrence,0.7,e129
MET,gastric cancer,biomarker_cancer_cooccurrence,"Co-occurrence in text: Initial Therapeutic Approach with Pembrolizumab in Synchronous Multiple Cancers, Including Non-Small Cell Lung Cancer, Highly Positive for Programmed Death-Ligand 1 Expression.. Treatment of synchrono...",cooccurrence,0.7,e130
PD-L1,gastric cancer,biomarker_cancer_cooccurrence,"Co-occurrence in text: Initial Therapeutic Approach with Pembrolizumab in Synchronous Multiple Cancers, Including Non-Small Cell Lung Cancer, Highly Positive for Programmed Death-Ligand 1 Expression.. Treatment of synchrono...",cooccurrence,0.7,e131
PR,gastric cancer,biomarker_cancer_cooccurrence,"Co-occurrence in text: Initial Therapeutic Approach with Pembrolizumab in Synchronous Multiple Cancers, Including Non-Small Cell Lung Cancer, Highly Positive for Programmed Death-Ligand 1 Expression.. Treatment of synchrono...",cooccurrence,0.7,e132
cisplatin,EGFR,drug_gene_cooccurrence,Co-occurrence in text: Adjuvant Immunotherapy in Patients with Early-Stage Non-small Cell Lung Cancer and Future Directions.. While cisplatin-based adjuvant chemotherapy has been the standard of care for the past two decade...,cooccurrence,0.6,e133
atezolizumab,MYC,drug_gene_cooccurrence,"Co-occurrence in text: Gastrointestinal toxicity of systemic oncology immunotherapy.. Systemic anti-cancer immunotherapy provides a substantial progress in options of current oncology treatment. Yet, this therapeutic approa...",cooccurrence,0.6,e134
ipilimumab,MYC,drug_gene_cooccurrence,"Co-occurrence in text: Gastrointestinal toxicity of systemic oncology immunotherapy.. Systemic anti-cancer immunotherapy provides a substantial progress in options of current oncology treatment. Yet, this therapeutic approa...",cooccurrence,0.6,e135
pembrolizumab,MYC,drug_gene_cooccurrence,"Co-occurrence in text: Gastrointestinal toxicity of systemic oncology immunotherapy.. Systemic anti-cancer immunotherapy provides a substantial progress in options of current oncology treatment. Yet, this therapeutic approa...",cooccurrence,0.6,e136
AR,colorectal cancer,biomarker_cancer_cooccurrence,"Co-occurrence in text: Gastrointestinal toxicity of systemic oncology immunotherapy.. Systemic anti-cancer immunotherapy provides a substantial progress in options of current oncology treatment. Yet, this therapeutic approa...",cooccurrence,0.7,e137
ER,colorectal cancer,biomarker_cancer_cooccurrence,"Co-occurrence in text: Gastrointestinal toxicity of systemic oncology immunotherapy.. Systemic anti-cancer immunotherapy provides a substantial progress in options of current oncology treatment. Yet, this therapeutic approa...",cooccurrence,0.7,e138
MET,colorectal cancer,biomarker_cancer_cooccurrence,"Co-occurrence in text: Gastrointestinal toxicity of systemic oncology immunotherapy.. Systemic anti-cancer immunotherapy provides a substantial progress in options of current oncology treatment. Yet, this therapeutic approa...",cooccurrence,0.7,e139
PD-L1,colorectal cancer,biomarker_cancer_cooccurrence,"Co-occurrence in text: Gastrointestinal toxicity of systemic oncology immunotherapy.. Systemic anti-cancer immunotherapy provides a substantial progress in options of current oncology treatment. Yet, this therapeutic approa...",cooccurrence,0.7,e140
PR,colorectal cancer,biomarker_cancer_cooccurrence,"Co-occurrence in text: Gastrointestinal toxicity of systemic oncology immunotherapy.. Systemic anti-cancer immunotherapy provides a substantial progress in options of current oncology treatment. Yet, this therapeutic approa...",cooccurrence,0.7,e141
AR,leukemia,biomarker_cancer_cooccurrence,"Co-occurrence in text: Development of Acute Adult T-cell Leukemia Following PD-1 Blockade Therapy for Lung Cancer.. Immune checkpoint inhibitors (ICIs) are widely used for the treatment of various cancers. However, paradoxi...",cooccurrence,0.7,e142
ER,leukemia,biomarker_cancer_cooccurrence,"Co-occurrence in text: Development of Acute Adult T-cell Leukemia Following PD-1 Blockade Therapy for Lung Cancer.. Immune checkpoint inhibitors (ICIs) are widely used for the treatment of various cancers. However, paradoxi...",cooccurrence,0.7,e143
PD-L1,leukemia,biomarker_cancer_cooccurrence,"Co-occurrence in text: Development of Acute Adult T-cell Leukemia Following PD-1 Blockade Therapy for Lung Cancer.. Immune checkpoint inhibitors (ICIs) are widely used for the treatment of various cancers. However, paradoxi...",cooccurrence,0.7,e144
PR,leukemia,biomarker_cancer_cooccurrence,"Co-occurrence in text: Development of Acute Adult T-cell Leukemia Following PD-1 Blockade Therapy for Lung Cancer.. Immune checkpoint inhibitors (ICIs) are widely used for the treatment of various cancers. However, paradoxi...",cooccurrence,0.7,e145
pembrolizumab,ROS1,drug_gene_cooccurrence,Co-occurrence in text: Validation of E1L3N antibody for PD-L1 detection and prediction of pembrolizumab response in non-small-cell lung cancer.. The programmed death-ligand 1 (PD-L1) 22C3 assay is one of the approved compan...,cooccurrence,0.6,e146
ROS1,lung cancer,biomarker_cancer_cooccurrence,Co-occurrence in text: Validation of E1L3N antibody for PD-L1 detection and prediction of pembrolizumab response in non-small-cell lung cancer.. The programmed death-ligand 1 (PD-L1) 22C3 assay is one of the approved compan...,cooccurrence,0.7,e147
ROS1,non-small cell lung cancer,biomarker_cancer_cooccurrence,Co-occurrence in text: Validation of E1L3N antibody for PD-L1 detection and prediction of pembrolizumab response in non-small-cell lung cancer.. The programmed death-ligand 1 (PD-L1) 22C3 assay is one of the approved compan...,cooccurrence,0.7,e148
nivolumab,APC,drug_gene_cooccurrence,Co-occurrence in text: Prognostic value of hematologic parameters in advanced non-small cell lung cancer patients receiving anti-PD-1 inhibitors.. The association between hematologic parameters and anti-programmed death-1 (...,cooccurrence,0.6,e149
pembrolizumab,APC,drug_gene_cooccurrence,Co-occurrence in text: Prognostic value of hematologic parameters in advanced non-small cell lung cancer patients receiving anti-PD-1 inhibitors.. The association between hematologic parameters and anti-programmed death-1 (...,cooccurrence,0.6,e150
KRAS,non-small cell lung cancer,biomarker_cancer_cooccurrence,Co-occurrence in text: Impact of KRAS G12C mutation in patients with advanced non-squamous non-small cell lung cancer treated with first-line pembrolizumab monotherapy.. Few data are available on the impact of KRAS mutation...,cooccurrence,0.7,e151
RET,melanoma,biomarker_cancer_cooccurrence,"Co-occurrence in text: Immune checkpoint inhibitors in patients aged 80 or older with advanced non-small cell lung cancer or melanoma: a real-life multicentre study.. Data regarding characteristics, safety and survival outc...",cooccurrence,0.7,e152
AR,endometrial cancer,biomarker_cancer_cooccurrence,"Co-occurrence in text: Dostarlimab: A breakthrough in the field of oncology.. Of the 19 million cancer cases reported worldwide in 2020, colorectal cancer (CRC) has a 10% prevalence and 9.4% mortality. A critical lack of ca...",cooccurrence,0.7,e153
ER,endometrial cancer,biomarker_cancer_cooccurrence,"Co-occurrence in text: Dostarlimab: A breakthrough in the field of oncology.. Of the 19 million cancer cases reported worldwide in 2020, colorectal cancer (CRC) has a 10% prevalence and 9.4% mortality. A critical lack of ca...",cooccurrence,0.7,e154
MET,endometrial cancer,biomarker_cancer_cooccurrence,"Co-occurrence in text: Dostarlimab: A breakthrough in the field of oncology.. Of the 19 million cancer cases reported worldwide in 2020, colorectal cancer (CRC) has a 10% prevalence and 9.4% mortality. A critical lack of ca...",cooccurrence,0.7,e155
PD-L1,endometrial cancer,biomarker_cancer_cooccurrence,"Co-occurrence in text: Dostarlimab: A breakthrough in the field of oncology.. Of the 19 million cancer cases reported worldwide in 2020, colorectal cancer (CRC) has a 10% prevalence and 9.4% mortality. A critical lack of ca...",cooccurrence,0.7,e156
PR,endometrial cancer,biomarker_cancer_cooccurrence,"Co-occurrence in text: Dostarlimab: A breakthrough in the field of oncology.. Of the 19 million cancer cases reported worldwide in 2020, colorectal cancer (CRC) has a 10% prevalence and 9.4% mortality. A critical lack of ca...",cooccurrence,0.7,e157
pembrolizumab,BRCA1,drug_gene_cooccurrence,Co-occurrence in text: Does Molecular Profiling of . Background: Several studies suggest that patients with KRAS-mutant NSCLC fail to benefit from standard systemic therapies and do not respond to EGFR inhibitors. Most rece...,cooccurrence,0.6,e158
docetaxel,ipilimumab,drug_drug_cooccurrence,Co-occurrence in text: Therapy for Stage IV Non-Small-Cell Lung Cancer Without Driver Alterations: ASCO Living Guideline.. To provide evidence-based recommendations updating the 2020 ASCO and Ontario Health (Cancer Care Ont...,cooccurrence,0.5,e159
atezolizumab,osimertinib,drug_drug_cooccurrence,Co-occurrence in text: Targeted Therapy and Immunotherapy in Early-Stage Non-Small Cell Lung Cancer: Current Evidence and Ongoing Trials.. The scenario of neoadjuvant and adjuvant settings in non-small cell lung cancer (NSC...,cooccurrence,0.5,e160
nivolumab,osimertinib,drug_drug_cooccurrence,Co-occurrence in text: Targeted Therapy and Immunotherapy in Early-Stage Non-Small Cell Lung Cancer: Current Evidence and Ongoing Trials.. The scenario of neoadjuvant and adjuvant settings in non-small cell lung cancer (NSC...,cooccurrence,0.5,e161
osimertinib,ALK,drug_gene_cooccurrence,Co-occurrence in text: Targeted Therapy and Immunotherapy in Early-Stage Non-Small Cell Lung Cancer: Current Evidence and Ongoing Trials.. The scenario of neoadjuvant and adjuvant settings in non-small cell lung cancer (NSC...,cooccurrence,0.6,e162
osimertinib,EGFR,drug_gene_cooccurrence,Co-occurrence in text: Targeted Therapy and Immunotherapy in Early-Stage Non-Small Cell Lung Cancer: Current Evidence and Ongoing Trials.. The scenario of neoadjuvant and adjuvant settings in non-small cell lung cancer (NSC...,cooccurrence,0.6,e163
carboplatin,ALK,drug_gene_cooccurrence,Co-occurrence in text: Deletions on 9p21 are associated with worse outcomes after anti-PD-1/PD-L1 monotherapy but not chemoimmunotherapy.. NCCN guidelines for first-line treatment of advanced non-squamous non-small-cell lun...,cooccurrence,0.6,e164
carboplatin,CDKN2A,drug_gene_cooccurrence,Co-occurrence in text: Deletions on 9p21 are associated with worse outcomes after anti-PD-1/PD-L1 monotherapy but not chemoimmunotherapy.. NCCN guidelines for first-line treatment of advanced non-squamous non-small-cell lun...,cooccurrence,0.6,e165
carboplatin,EGFR,drug_gene_cooccurrence,Co-occurrence in text: Deletions on 9p21 are associated with worse outcomes after anti-PD-1/PD-L1 monotherapy but not chemoimmunotherapy.. NCCN guidelines for first-line treatment of advanced non-squamous non-small-cell lun...,cooccurrence,0.6,e166
cisplatin,ALK,drug_gene_cooccurrence,Co-occurrence in text: Deletions on 9p21 are associated with worse outcomes after anti-PD-1/PD-L1 monotherapy but not chemoimmunotherapy.. NCCN guidelines for first-line treatment of advanced non-squamous non-small-cell lun...,cooccurrence,0.6,e167
cisplatin,CDKN2A,drug_gene_cooccurrence,Co-occurrence in text: Deletions on 9p21 are associated with worse outcomes after anti-PD-1/PD-L1 monotherapy but not chemoimmunotherapy.. NCCN guidelines for first-line treatment of advanced non-squamous non-small-cell lun...,cooccurrence,0.6,e168
pembrolizumab,CDKN2A,drug_gene_cooccurrence,Co-occurrence in text: Deletions on 9p21 are associated with worse outcomes after anti-PD-1/PD-L1 monotherapy but not chemoimmunotherapy.. NCCN guidelines for first-line treatment of advanced non-squamous non-small-cell lun...,cooccurrence,0.6,e169
pembrolizumab,BRAF,drug_gene_cooccurrence,Co-occurrence in text: Very high PD-L1 expression as a prognostic indicator of overall survival among patients with advanced non-small cell lung cancer receiving anti-PD-(L)1 monotherapies in routine practice.. Programmed d...,cooccurrence,0.6,e170
BRAF,lung cancer,biomarker_cancer_cooccurrence,Co-occurrence in text: Very high PD-L1 expression as a prognostic indicator of overall survival among patients with advanced non-small cell lung cancer receiving anti-PD-(L)1 monotherapies in routine practice.. Programmed d...,cooccurrence,0.7,e171
BRAF,non-small cell lung cancer,biomarker_cancer_cooccurrence,Co-occurrence in text: Very high PD-L1 expression as a prognostic indicator of overall survival among patients with advanced non-small cell lung cancer receiving anti-PD-(L)1 monotherapies in routine practice.. Programmed d...,cooccurrence,0.7,e172
AR,head and neck cancer,biomarker_cancer_cooccurrence,Co-occurrence in text: Prolonged Response of Metastatic Programmed Death-Ligand 1 (PD-L1) Negative Basaloid Squamous Cell Carcinoma of the Lung to Maintenance Immunotherapy.. Basaloid squamous cell carcinoma (BSCC) is a var...,cooccurrence,0.7,e173
ER,head and neck cancer,biomarker_cancer_cooccurrence,Co-occurrence in text: Prolonged Response of Metastatic Programmed Death-Ligand 1 (PD-L1) Negative Basaloid Squamous Cell Carcinoma of the Lung to Maintenance Immunotherapy.. Basaloid squamous cell carcinoma (BSCC) is a var...,cooccurrence,0.7,e174
MET,head and neck cancer,biomarker_cancer_cooccurrence,Co-occurrence in text: Prolonged Response of Metastatic Programmed Death-Ligand 1 (PD-L1) Negative Basaloid Squamous Cell Carcinoma of the Lung to Maintenance Immunotherapy.. Basaloid squamous cell carcinoma (BSCC) is a var...,cooccurrence,0.7,e175
PD-L1,head and neck cancer,biomarker_cancer_cooccurrence,Co-occurrence in text: Prolonged Response of Metastatic Programmed Death-Ligand 1 (PD-L1) Negative Basaloid Squamous Cell Carcinoma of the Lung to Maintenance Immunotherapy.. Basaloid squamous cell carcinoma (BSCC) is a var...,cooccurrence,0.7,e176
PR,head and neck cancer,biomarker_cancer_cooccurrence,Co-occurrence in text: Prolonged Response of Metastatic Programmed Death-Ligand 1 (PD-L1) Negative Basaloid Squamous Cell Carcinoma of the Lung to Maintenance Immunotherapy.. Basaloid squamous cell carcinoma (BSCC) is a var...,cooccurrence,0.7,e177
pembrolizumab,RB1,drug_gene_cooccurrence,"Co-occurrence in text: Clinicopathologic and Genomic Landscape of Non-Small Cell Lung Cancer Brain Metastases.. In patients with non-small cell lung cancer (NSCLC), 10%-40% will eventually develop brain metastases. We prese...",cooccurrence,0.6,e178
osimertinib,pembrolizumab,drug_drug_cooccurrence,Co-occurrence in text: Neoadjuvant and Adjuvant Systemic Therapy for Early-Stage Non-small-Cell Lung Cancer.. Approximately a third of patients with non-small-cell lung cancer (NSCLC) present with surgically resectable dise...,cooccurrence,0.5,e179
atezolizumab,carboplatin,drug_drug_cooccurrence,"Co-occurrence in text: [A Case of Non-Small Cell Lung Cancer Successfully Treated with Anti-PD-L1 Therapy after Exacerbation Caused by Anti-PD-1 Therapy].. A 52-year-old male was diagnosed with cT4N3M1b, cStage Ⅳ adenocarci...",cooccurrence,0.5,e180
carboplatin,docetaxel,drug_drug_cooccurrence,"Co-occurrence in text: [A Case of Non-Small Cell Lung Cancer Successfully Treated with Anti-PD-L1 Therapy after Exacerbation Caused by Anti-PD-1 Therapy].. A 52-year-old male was diagnosed with cT4N3M1b, cStage Ⅳ adenocarci...",cooccurrence,0.5,e181
pembrolizumab,JAK2,drug_gene_cooccurrence,"Co-occurrence in text: Gene expression profile of high PD-L1 non-small cell lung cancers refractory to pembrolizumab.. Despite high expression of PD-L1, around half of advanced non-small cell lung cancer (NSCLC) will not ex...",cooccurrence,0.6,e182
pembrolizumab,PTEN,drug_gene_cooccurrence,"Co-occurrence in text: Gene expression profile of high PD-L1 non-small cell lung cancers refractory to pembrolizumab.. Despite high expression of PD-L1, around half of advanced non-small cell lung cancer (NSCLC) will not ex...",cooccurrence,0.6,e183
PTEN,lung cancer,biomarker_cancer_cooccurrence,"Co-occurrence in text: Gene expression profile of high PD-L1 non-small cell lung cancers refractory to pembrolizumab.. Despite high expression of PD-L1, around half of advanced non-small cell lung cancer (NSCLC) will not ex...",cooccurrence,0.7,e184
PTEN,non-small cell lung cancer,biomarker_cancer_cooccurrence,"Co-occurrence in text: Gene expression profile of high PD-L1 non-small cell lung cancers refractory to pembrolizumab.. Despite high expression of PD-L1, around half of advanced non-small cell lung cancer (NSCLC) will not ex...",cooccurrence,0.7,e185
cetuximab,nivolumab,drug_drug_cooccurrence,Co-occurrence in text: Anti-tumor activity of cetuximab plus avelumab in non-small cell lung cancer patients involves innate immunity activation: findings from the CAVE-Lung trial.. We recently conducted Cetuximab-AVElumab-...,cooccurrence,0.5,e186
cetuximab,pembrolizumab,drug_drug_cooccurrence,Co-occurrence in text: Anti-tumor activity of cetuximab plus avelumab in non-small cell lung cancer patients involves innate immunity activation: findings from the CAVE-Lung trial.. We recently conducted Cetuximab-AVElumab-...,cooccurrence,0.5,e187
cetuximab,EGFR,drug_gene_cooccurrence,Co-occurrence in text: Anti-tumor activity of cetuximab plus avelumab in non-small cell lung cancer patients involves innate immunity activation: findings from the CAVE-Lung trial.. We recently conducted Cetuximab-AVElumab-...,cooccurrence,0.6,e188
cisplatin,HER2,drug_gene_cooccurrence,Co-occurrence in text: Case Report: Tumor Microenvironment Characteristics in a Patient With HER2 Mutant Lung Squamous Cell Carcinoma Harboring High PD-L1 Expression Who Presented Hyperprogressive Disease.. High PD-L1 expre...,cooccurrence,0.6,e189
docetaxel,HER2,drug_gene_cooccurrence,Co-occurrence in text: Case Report: Tumor Microenvironment Characteristics in a Patient With HER2 Mutant Lung Squamous Cell Carcinoma Harboring High PD-L1 Expression Who Presented Hyperprogressive Disease.. High PD-L1 expre...,cooccurrence,0.6,e190
RET,breast cancer,biomarker_cancer_cooccurrence,Co-occurrence in text: Integrin signaling gene alterations and outcomes of cancer patients receiving immune checkpoint inhibitors.. Immune evasion is a hallmark of cancer and is associated with resistance to PD-1/PD-L1 and ...,cooccurrence,0.7,e191
gefitinib,pembrolizumab,drug_drug_cooccurrence,Co-occurrence in text: Clinical Effectiveness of Immune Checkpoint Inhibitors in Non-Small-Cell Lung Cancer with a Poor Performance Status.. Immune checkpoint inhibitors (ICIs) are standard treatments for patients with lung...,cooccurrence,0.5,e192
FGFR,lung cancer,biomarker_cancer_cooccurrence,Co-occurrence in text: Case Report: Anlotinib Reverses Nivolumab Resistance in Advanced Primary Pulmonary Lymphoepithelioma-Like Carcinoma With FGFR3 Gene Amplification.. Primary pulmonary lymphoepithelioma-like carcinoma (...,cooccurrence,0.7,e193
FGFR,non-small cell lung cancer,biomarker_cancer_cooccurrence,Co-occurrence in text: Case Report: Anlotinib Reverses Nivolumab Resistance in Advanced Primary Pulmonary Lymphoepithelioma-Like Carcinoma With FGFR3 Gene Amplification.. Primary pulmonary lymphoepithelioma-like carcinoma (...,cooccurrence,0.7,e194
nivolumab,ipilimumab,drug_synergy,"Pattern match ((?:combination|co[\s-]?administration)\s+of\s+(?P<drug1>\w+)\s+and\s+(?P<drug2>\w+)): combination of nivolumab and ipilimumab drugs, smokers had, on average, reduced HR and FE...",pattern,0.8,e195
nivolumab,ipilimumab,drug_combination_regimen,"combination of nivolumab and ipilimumab drugs, smokers had, on average, reduced HR and FE model meta-analysis values (0.257 and 0.141), res",pattern,0.9,e196
cisplatin,KRAS,drug_gene_cooccurrence,"Co-occurrence in text: Phase 1, pharmacogenomic, dose-expansion study of pegargiminase plus pemetrexed and cisplatin in patients with ASS1-deficient non-squamous non-small cell lung cancer.. We evaluated the arginine-deplet...",cooccurrence,0.6,e197
MSI,lung cancer,biomarker_cancer_cooccurrence,Co-occurrence in text: Poor performance status patient with long-lasting major response to pembrolizumab in advanced non-small-cell lung cancer with coexisting POLE mutation and deficient mismatch repair pathway.. Immunothe...,cooccurrence,0.7,e198
AR,cervical cancer,biomarker_cancer_cooccurrence,Co-occurrence in text: Early presentation of pembrolizumab-associated pneumonitis.. Pembrolizumab is a selective anti-PD-L1 humanised monoclonal antibody approved by the Food and Drug Administration for treating multiple ca...,cooccurrence,0.7,e199
ER,cervical cancer,biomarker_cancer_cooccurrence,Co-occurrence in text: Early presentation of pembrolizumab-associated pneumonitis.. Pembrolizumab is a selective anti-PD-L1 humanised monoclonal antibody approved by the Food and Drug Administration for treating multiple ca...,cooccurrence,0.7,e200
PD-L1,cervical cancer,biomarker_cancer_cooccurrence,Co-occurrence in text: Early presentation of pembrolizumab-associated pneumonitis.. Pembrolizumab is a selective anti-PD-L1 humanised monoclonal antibody approved by the Food and Drug Administration for treating multiple ca...,cooccurrence,0.7,e201
PR,cervical cancer,biomarker_cancer_cooccurrence,Co-occurrence in text: Early presentation of pembrolizumab-associated pneumonitis.. Pembrolizumab is a selective anti-PD-L1 humanised monoclonal antibody approved by the Food and Drug Administration for treating multiple ca...,cooccurrence,0.7,e202
gefitinib,EGFR,drug_gene_cooccurrence,"Co-occurrence in text: Case Report: Re-Sensitization to Gefitinib in Lung Adenocarcinoma Harboring EGFR Mutation and High PD-L1 Expression After Immunotherapy Resistance, Which Finally Transform Into Small Cell Carcinoma.. ...",cooccurrence,0.6,e203
carboplatin,ROS1,drug_gene_cooccurrence,"Co-occurrence in text: Nivolumab with carboplatin, paclitaxel, and bevacizumab for first-line treatment of advanced nonsquamous non-small-cell lung cancer.. This international, randomized, double-blind phase III study (ONO-...",cooccurrence,0.6,e204
nivolumab,ROS1,drug_gene_cooccurrence,"Co-occurrence in text: Nivolumab with carboplatin, paclitaxel, and bevacizumab for first-line treatment of advanced nonsquamous non-small-cell lung cancer.. This international, randomized, double-blind phase III study (ONO-...",cooccurrence,0.6,e205
paclitaxel,ALK,drug_gene_cooccurrence,"Co-occurrence in text: Nivolumab with carboplatin, paclitaxel, and bevacizumab for first-line treatment of advanced nonsquamous non-small-cell lung cancer.. This international, randomized, double-blind phase III study (ONO-...",cooccurrence,0.6,e206
paclitaxel,EGFR,drug_gene_cooccurrence,"Co-occurrence in text: Nivolumab with carboplatin, paclitaxel, and bevacizumab for first-line treatment of advanced nonsquamous non-small-cell lung cancer.. This international, randomized, double-blind phase III study (ONO-...",cooccurrence,0.6,e207
paclitaxel,ROS1,drug_gene_cooccurrence,"Co-occurrence in text: Nivolumab with carboplatin, paclitaxel, and bevacizumab for first-line treatment of advanced nonsquamous non-small-cell lung cancer.. This international, randomized, double-blind phase III study (ONO-...",cooccurrence,0.6,e208
RET,lymphoma,biomarker_cancer_cooccurrence,Co-occurrence in text: [A Case Report of Checkpoint Inhibitor Pneumonitis Caused by PD-1Antibody-Safety and Effectiveness of Pirfenidone].. Immune checkpoint inhibitor associated pneumonia (CIP) is a serious side effect of...,cooccurrence,0.7,e209
ROS1,lymphoma,biomarker_cancer_cooccurrence,Co-occurrence in text: [A Case Report of Checkpoint Inhibitor Pneumonitis Caused by PD-1Antibody-Safety and Effectiveness of Pirfenidone].. Immune checkpoint inhibitor associated pneumonia (CIP) is a serious side effect of...,cooccurrence,0.7,e210
nivolumab,docetaxel,drug_synergy,Pattern match ((?:combination|co[\s-]?administration)\s+of\s+(?P<drug1>\w+)\s+and\s+(?P<drug2>\w+)): combination of nivolumab and docetaxel demonstrated a meaningful improvement in progress...,pattern,0.8,e211
nivolumab,docetaxel,drug_combination_regimen,combination of nivolumab and docetaxel demonstrated a meaningful improvement in progression-free survival and overall survival compared to,pattern,0.9,e212
TMB,melanoma,biomarker_cancer_cooccurrence,Co-occurrence in text: TMB or not TMB as a biomarker: That is the question.. Immune checkpoint inhibitors (ICIs) have revolutionized the landscape of therapeutic options for many cancers. These treatments have demonstrated ...,cooccurrence,0.7,e213
pembrolizumab,NF1,drug_gene_cooccurrence,Co-occurrence in text: A case of dramatic reduction in cancer-associated thrombus following initiation of pembrolizumab in patient with a poor performance status and PD-L1. Pembrolizumab is a standard treatment for non-smal...,cooccurrence,0.6,e214
cyclophosphamide,pembrolizumab,drug_drug_cooccurrence,Co-occurrence in text: Refractory Bullous Pemphigoid in a Patient with Metastatic Lung Adenocarcinoma Treated with Pembrolizumab.. We present the case of a 73-year-old male patient with a history of tobacco use who presente...,cooccurrence,0.5,e215
cyclophosphamide,MET,drug_gene_cooccurrence,Co-occurrence in text: Refractory Bullous Pemphigoid in a Patient with Metastatic Lung Adenocarcinoma Treated with Pembrolizumab.. We present the case of a 73-year-old male patient with a history of tobacco use who presente...,cooccurrence,0.6,e216
atezolizumab,trastuzumab,drug_drug_cooccurrence,"Co-occurrence in text: ASCO 2020 non-small lung cancer (NSCLC) personal highlights.. In this article we summarize our personal non-small cell lung cancer (NSCLC) highlights of the virtual ASCO 2020 meeting, covering develop...",cooccurrence,0.5,e217
ipilimumab,osimertinib,drug_drug_cooccurrence,"Co-occurrence in text: ASCO 2020 non-small lung cancer (NSCLC) personal highlights.. In this article we summarize our personal non-small cell lung cancer (NSCLC) highlights of the virtual ASCO 2020 meeting, covering develop...",cooccurrence,0.5,e218
ipilimumab,trastuzumab,drug_drug_cooccurrence,"Co-occurrence in text: ASCO 2020 non-small lung cancer (NSCLC) personal highlights.. In this article we summarize our personal non-small cell lung cancer (NSCLC) highlights of the virtual ASCO 2020 meeting, covering develop...",cooccurrence,0.5,e219
nivolumab,trastuzumab,drug_drug_cooccurrence,"Co-occurrence in text: ASCO 2020 non-small lung cancer (NSCLC) personal highlights.. In this article we summarize our personal non-small cell lung cancer (NSCLC) highlights of the virtual ASCO 2020 meeting, covering develop...",cooccurrence,0.5,e220
osimertinib,trastuzumab,drug_drug_cooccurrence,"Co-occurrence in text: ASCO 2020 non-small lung cancer (NSCLC) personal highlights.. In this article we summarize our personal non-small cell lung cancer (NSCLC) highlights of the virtual ASCO 2020 meeting, covering develop...",cooccurrence,0.5,e221
pembrolizumab,trastuzumab,drug_drug_cooccurrence,"Co-occurrence in text: ASCO 2020 non-small lung cancer (NSCLC) personal highlights.. In this article we summarize our personal non-small cell lung cancer (NSCLC) highlights of the virtual ASCO 2020 meeting, covering develop...",cooccurrence,0.5,e222
atezolizumab,HER2,drug_gene_cooccurrence,"Co-occurrence in text: ASCO 2020 non-small lung cancer (NSCLC) personal highlights.. In this article we summarize our personal non-small cell lung cancer (NSCLC) highlights of the virtual ASCO 2020 meeting, covering develop...",cooccurrence,0.6,e223
ipilimumab,HER2,drug_gene_cooccurrence,"Co-occurrence in text: ASCO 2020 non-small lung cancer (NSCLC) personal highlights.. In this article we summarize our personal non-small cell lung cancer (NSCLC) highlights of the virtual ASCO 2020 meeting, covering develop...",cooccurrence,0.6,e224
nivolumab,HER2,drug_gene_cooccurrence,"Co-occurrence in text: ASCO 2020 non-small lung cancer (NSCLC) personal highlights.. In this article we summarize our personal non-small cell lung cancer (NSCLC) highlights of the virtual ASCO 2020 meeting, covering develop...",cooccurrence,0.6,e225
osimertinib,HER2,drug_gene_cooccurrence,"Co-occurrence in text: ASCO 2020 non-small lung cancer (NSCLC) personal highlights.. In this article we summarize our personal non-small cell lung cancer (NSCLC) highlights of the virtual ASCO 2020 meeting, covering develop...",cooccurrence,0.6,e226
trastuzumab,EGFR,drug_gene_cooccurrence,"Co-occurrence in text: ASCO 2020 non-small lung cancer (NSCLC) personal highlights.. In this article we summarize our personal non-small cell lung cancer (NSCLC) highlights of the virtual ASCO 2020 meeting, covering develop...",cooccurrence,0.6,e227
trastuzumab,HER2,drug_gene_cooccurrence,"Co-occurrence in text: ASCO 2020 non-small lung cancer (NSCLC) personal highlights.. In this article we summarize our personal non-small cell lung cancer (NSCLC) highlights of the virtual ASCO 2020 meeting, covering develop...",cooccurrence,0.6,e228
docetaxel,erlotinib,drug_drug_cooccurrence,Co-occurrence in text: Biomarker-driven therapies for previously treated squamous non-small-cell lung cancer (Lung-MAP SWOG S1400): a biomarker-driven master protocol.. The Lung Cancer Master Protocol (Lung-MAP; S1400) is a...,cooccurrence,0.5,e229
erlotinib,ipilimumab,drug_drug_cooccurrence,Co-occurrence in text: Biomarker-driven therapies for previously treated squamous non-small-cell lung cancer (Lung-MAP SWOG S1400): a biomarker-driven master protocol.. The Lung Cancer Master Protocol (Lung-MAP; S1400) is a...,cooccurrence,0.5,e230
erlotinib,nivolumab,drug_drug_cooccurrence,Co-occurrence in text: Biomarker-driven therapies for previously treated squamous non-small-cell lung cancer (Lung-MAP SWOG S1400): a biomarker-driven master protocol.. The Lung Cancer Master Protocol (Lung-MAP; S1400) is a...,cooccurrence,0.5,e231
docetaxel,PIK3CA,drug_gene_cooccurrence,Co-occurrence in text: Biomarker-driven therapies for previously treated squamous non-small-cell lung cancer (Lung-MAP SWOG S1400): a biomarker-driven master protocol.. The Lung Cancer Master Protocol (Lung-MAP; S1400) is a...,cooccurrence,0.6,e232
erlotinib,MET,drug_gene_cooccurrence,Co-occurrence in text: Biomarker-driven therapies for previously treated squamous non-small-cell lung cancer (Lung-MAP SWOG S1400): a biomarker-driven master protocol.. The Lung Cancer Master Protocol (Lung-MAP; S1400) is a...,cooccurrence,0.6,e233
erlotinib,PIK3CA,drug_gene_cooccurrence,Co-occurrence in text: Biomarker-driven therapies for previously treated squamous non-small-cell lung cancer (Lung-MAP SWOG S1400): a biomarker-driven master protocol.. The Lung Cancer Master Protocol (Lung-MAP; S1400) is a...,cooccurrence,0.6,e234
ipilimumab,PIK3CA,drug_gene_cooccurrence,Co-occurrence in text: Biomarker-driven therapies for previously treated squamous non-small-cell lung cancer (Lung-MAP SWOG S1400): a biomarker-driven master protocol.. The Lung Cancer Master Protocol (Lung-MAP; S1400) is a...,cooccurrence,0.6,e235
nivolumab,PIK3CA,drug_gene_cooccurrence,Co-occurrence in text: Biomarker-driven therapies for previously treated squamous non-small-cell lung cancer (Lung-MAP SWOG S1400): a biomarker-driven master protocol.. The Lung Cancer Master Protocol (Lung-MAP; S1400) is a...,cooccurrence,0.6,e236
PIK3CA,lung cancer,biomarker_cancer_cooccurrence,Co-occurrence in text: Biomarker-driven therapies for previously treated squamous non-small-cell lung cancer (Lung-MAP SWOG S1400): a biomarker-driven master protocol.. The Lung Cancer Master Protocol (Lung-MAP; S1400) is a...,cooccurrence,0.7,e237
carboplatin,BRAF,drug_gene_cooccurrence,Co-occurrence in text: Pembrolizumab plus platinum-based chemotherapy for unfavorable cancer of unknown primary site: Case report.. We report a case of sustained complete response in unfavorable cancer of unknown primary si...,cooccurrence,0.6,e238
cisplatin,BRAF,drug_gene_cooccurrence,Co-occurrence in text: Pembrolizumab plus platinum-based chemotherapy for unfavorable cancer of unknown primary site: Case report.. We report a case of sustained complete response in unfavorable cancer of unknown primary si...,cooccurrence,0.6,e239
cisplatin,ROS1,drug_gene_cooccurrence,Co-occurrence in text: Pembrolizumab plus platinum-based chemotherapy for unfavorable cancer of unknown primary site: Case report.. We report a case of sustained complete response in unfavorable cancer of unknown primary si...,cooccurrence,0.6,e240
paclitaxel,trastuzumab,drug_drug_cooccurrence,"Co-occurrence in text: Basket Study of Neratinib in Participants With Solid Tumors Harboring Somatic HER2 or EGFR Exon 18 Mutations. This is an open-label, multicenter, multinational, Phase 2 basket study exploring the effi...",cooccurrence,0.5,e241
paclitaxel,HER2,drug_gene_cooccurrence,"Co-occurrence in text: Basket Study of Neratinib in Participants With Solid Tumors Harboring Somatic HER2 or EGFR Exon 18 Mutations. This is an open-label, multicenter, multinational, Phase 2 basket study exploring the effi...",cooccurrence,0.6,e242
carboplatin,paclitaxel,drug_synergy,"Pattern match ((?:combination|co[\s-]?administration)\s+of\s+(?P<drug1>\w+)\s+and\s+(?P<drug2>\w+)): combination of carboplatin and paclitaxel) and radiation in patients with lung cancer.

You...",pattern,0.8,e243
carboplatin,paclitaxel,drug_combination_regimen,"combination of carboplatin and paclitaxel) and radiation in patients with lung cancer.

You are being asked to take part in this study becaus",pattern,0.9,e244
carboplatin,HER2,drug_gene_cooccurrence,Co-occurrence in text: Beamion LUNG-2: A Study to Test Whether Zongertinib (BI 1810631) Helps People With Advanced Non-small Cell Lung Cancer With HER2 Mutations Compared With Standard Treatment. This study is open to adult...,cooccurrence,0.6,e245
lung cancer,her2,biomarker_cancer,Pattern match ((?P<cancer>\w+\s+cancer)\s+with\s+(?P<biomarker>\w+)\s+(?:mutation|amplification)): Lung Cancer With HER2 Mutations Compared With Standard Treatment. This study is ...,pattern,0.8,e246
AR,prostate cancer,biomarker_cancer_cooccurrence,"Co-occurrence in text: Standard Therapy With or Without Dalteparin in Treating Patients With Advanced Breast, Lung, Colorectal, or Prostate Cancer. RATIONALE: Dalteparin may be effective in inhibiting the growth of blood ve...",cooccurrence,0.7,e247
ER,prostate cancer,biomarker_cancer_cooccurrence,"Co-occurrence in text: Standard Therapy With or Without Dalteparin in Treating Patients With Advanced Breast, Lung, Colorectal, or Prostate Cancer. RATIONALE: Dalteparin may be effective in inhibiting the growth of blood ve...",cooccurrence,0.7,e248
MET,prostate cancer,biomarker_cancer_cooccurrence,"Co-occurrence in text: Standard Therapy With or Without Dalteparin in Treating Patients With Advanced Breast, Lung, Colorectal, or Prostate Cancer. RATIONALE: Dalteparin may be effective in inhibiting the growth of blood ve...",cooccurrence,0.7,e249
PR,prostate cancer,biomarker_cancer_cooccurrence,"Co-occurrence in text: Standard Therapy With or Without Dalteparin in Treating Patients With Advanced Breast, Lung, Colorectal, or Prostate Cancer. RATIONALE: Dalteparin may be effective in inhibiting the growth of blood ve...",cooccurrence,0.7,e250
BRAF,melanoma,biomarker_cancer_cooccurrence,Co-occurrence in text: XP-102 and XP-102 in Combination With Trametinib in Advanced Solid Tumor Patients With a BRAF V600 Mutation. This is a first-in-human multi-center study which will be conducted in advanced malignant s...,cooccurrence,0.7,e251
ER,pancreatic cancer,biomarker_cancer_cooccurrence,"Co-occurrence in text: Study of Covalent Menin Inhibitor BMF-219 in Adult Patients With KRAS Driven Non-Small Cell Lung Cancer, Pancreatic Cancer, and Colorectal Cancer. A Phase 1/1b dose finding study to determine the OBD(...",cooccurrence,0.7,e252
KRAS,colorectal cancer,biomarker_cancer_cooccurrence,"Co-occurrence in text: Study of Covalent Menin Inhibitor BMF-219 in Adult Patients With KRAS Driven Non-Small Cell Lung Cancer, Pancreatic Cancer, and Colorectal Cancer. A Phase 1/1b dose finding study to determine the OBD(...",cooccurrence,0.7,e253
KRAS,pancreatic cancer,biomarker_cancer_cooccurrence,"Co-occurrence in text: Study of Covalent Menin Inhibitor BMF-219 in Adult Patients With KRAS Driven Non-Small Cell Lung Cancer, Pancreatic Cancer, and Colorectal Cancer. A Phase 1/1b dose finding study to determine the OBD(...",cooccurrence,0.7,e254
MET,pancreatic cancer,biomarker_cancer_cooccurrence,"Co-occurrence in text: Study of Covalent Menin Inhibitor BMF-219 in Adult Patients With KRAS Driven Non-Small Cell Lung Cancer, Pancreatic Cancer, and Colorectal Cancer. A Phase 1/1b dose finding study to determine the OBD(...",cooccurrence,0.7,e255
erlotinib,pembrolizumab,drug_drug_cooccurrence,Co-occurrence in text: Brazilian Lung Immunotherapy Study. Immunotherapy with anti-PD-1/PD-L1 agents either as single agents or combined with chemotherapy is now considered the standard of care for patients with non-small-c...,cooccurrence,0.5,e256
erlotinib,ALK,drug_gene_cooccurrence,Co-occurrence in text: Brazilian Lung Immunotherapy Study. Immunotherapy with anti-PD-1/PD-L1 agents either as single agents or combined with chemotherapy is now considered the standard of care for patients with non-small-c...,cooccurrence,0.6,e257
cyclophosphamide,KRAS,drug_gene_cooccurrence,Co-occurrence in text: Autologous T-cells Genetically Engineered to Express Receptors Reactive Against KRAS Mutations in Conjunction With a Vaccine Directed Against These Antigens in Participants With Metastatic Cancer. Bac...,cooccurrence,0.6,e258
carboplatin,trastuzumab,drug_drug_cooccurrence,Co-occurrence in text: Interleukin-12 and Trastuzumab in Treating Patients With Cancer That Has High Levels of HER2/Neu. Interleukin-12 may kill tumor cells by stopping blood flow to the tumor and by stimulating a person's ...,cooccurrence,0.5,e259
osimertinib,MET,drug_gene_cooccurrence,"Co-occurrence in text: High-dose Furmonertinib in the Treatment in Patients With Advanced, Metastatic NSCLC With Progressed After First- or Second-line Treatment With Osimertinib. This is a prospective, randomised, uncontro...",cooccurrence,0.6,e260
paclitaxel,BRAF,drug_gene_cooccurrence,"Co-occurrence in text: A Phase 1/2a Study of IMM-1-104 in Participants With Advanced or Metastatic Solid Tumors. This is an open-label, dose-exploration and expansion study to determine the safety, tolerability, pharmacokin...",cooccurrence,0.6,e261
MSI,colorectal cancer,biomarker_cancer_cooccurrence,Co-occurrence in text: Nivolumab (Opdivo®) Plus ABI-009 (Nab-rapamycin) for Advanced Sarcoma and Certain Cancers. This study investigates the safety/toxicity and potential anti-tumor activity of sequential administration of...,cooccurrence,0.7,e262
MSI,hepatocellular carcinoma,biomarker_cancer_cooccurrence,Co-occurrence in text: Nivolumab (Opdivo®) Plus ABI-009 (Nab-rapamycin) for Advanced Sarcoma and Certain Cancers. This study investigates the safety/toxicity and potential anti-tumor activity of sequential administration of...,cooccurrence,0.7,e263
MSI,lymphoma,biomarker_cancer_cooccurrence,Co-occurrence in text: Nivolumab (Opdivo®) Plus ABI-009 (Nab-rapamycin) for Advanced Sarcoma and Certain Cancers. This study investigates the safety/toxicity and potential anti-tumor activity of sequential administration of...,cooccurrence,0.7,e264
MSI,melanoma,biomarker_cancer_cooccurrence,Co-occurrence in text: Nivolumab (Opdivo®) Plus ABI-009 (Nab-rapamycin) for Advanced Sarcoma and Certain Cancers. This study investigates the safety/toxicity and potential anti-tumor activity of sequential administration of...,cooccurrence,0.7,e265
MSI,non-small cell lung cancer,biomarker_cancer_cooccurrence,Co-occurrence in text: Nivolumab (Opdivo®) Plus ABI-009 (Nab-rapamycin) for Advanced Sarcoma and Certain Cancers. This study investigates the safety/toxicity and potential anti-tumor activity of sequential administration of...,cooccurrence,0.7,e266
MSI,renal cell carcinoma,biomarker_cancer_cooccurrence,Co-occurrence in text: Nivolumab (Opdivo®) Plus ABI-009 (Nab-rapamycin) for Advanced Sarcoma and Certain Cancers. This study investigates the safety/toxicity and potential anti-tumor activity of sequential administration of...,cooccurrence,0.7,e267
